Archives
-
EdU Imaging Kits (Cy5) for ccRCC Proliferation
2026-08-29
EdU Imaging Kits (Cy5) convert S-phase DNA synthesis into a sensitive, morphology-preserving readout for microscopy and flow cytometry. Applied to the NME3–mitochondrial dynamics study, the assay helps distinguish reduced proliferation after gene knockdown or TKI exposure from broader changes in cell health.
-
Lipid Peroxidation (MDA) Assay Kit in SA-AKI
2026-08-28
The Lipid Peroxidation (MDA) Assay Kit provides dual-mode malondialdehyde quantification for studying ferroptosis and oxidative injury in sepsis-associated acute kidney injury. This guide translates recent LCN2–AMPK/SIRT3/FOXO3a findings into practical assay design, controls, and interpretation decisions.
-
BIRB 796 Workflow for p38α MAPK Studies
2026-08-28
BIRB 796, also called Doramapimod, combines subnanomolar p38α engagement with an allosteric mechanism suited to inflammation, cytokine, and apoptosis workflows. This guide translates that profile into practical assay design, phosphatase-aware experiments, and troubleshooting strategies for reproducible research.
-
AP20187 Chemical Inducer of Dimerization Guide
2026-08-27
AP20187 enables time-controlled activation of engineered signaling proteins, making it useful for conditional gene expression, cell therapy, and metabolic assays. This guide connects practical CID workflows with a chronic intermittent hypoxia model to show how programmable activation can strengthen macrophage–nociceptor experiments without overstating the reference study’s findings.
-
Primidone Inhibits TRPM3 in Adenomyosis
2026-08-27
A 2025 study links increased TRP-channel expression with adenomyosis symptoms and tests Primidone as a pharmacological intervention in a tamoxifen-induced mouse model. The work identifies TRPM3 as a plausible analgesic and disease-modifying target while highlighting the need for clinical validation, target-engagement studies, and better dose translation.
-
CTCF, Centromere Function, and Mitotic Fidelity
2026-08-26
The reference study uses rapid, inducible CTCF degradation to show that CTCF maintains centromere mechanics, metaphase plate organization, accurate mitosis, and post-mitotic nuclear shape. Its findings distinguish CTCF loss from primary CENP-E recruitment defects and support a model in which CTCF contributes to centromeric chromatin function, potentially alongside cohesin.
-
GW4064: Practical FXR Activation Workflows
2026-08-26
GW4064 is a potent non-steroidal FXR agonist for separating receptor activation from downstream bile acid, lipid, and barrier phenotypes. This workflow-focused guide shows how to build reproducible FXR assays, test transporter rescue, and troubleshoot solubility, light sensitivity, and vehicle effects.
-
EZ Cap™ Mouse IL-12 mRNA: Research Workflow
2026-08-25
Build controlled mouse IL-12 expression studies with a capped, polyadenylated, m1Ψ-modified transcript designed for efficient translation and reduced innate RNA sensing. The workflow connects routine cell assays with emerging extrahepatic delivery platforms, including virus-mimicking particles for lung and spleen research.
-
Epalrestat Workflows for Polyol Pathway Research
2026-08-25
Build reproducible Epalrestat experiments for aldose reductase inhibition, diabetic complication studies, oxidative stress research, and neuroprotection. A practical workflow also shows how the compound can support hypothesis-driven cancer metabolism assays without overstating the current evidence.
-
GSK-923295: CENP-E Inhibition Workflows
2026-08-24
GSK-923295 provides a precise pharmacological route to study CENP-E-dependent chromosome congression, mitotic arrest, and tumor-cell response. This guide connects dose-response assays with the centromere-focused findings from CTCF depletion studies, while emphasizing solvent control, timing, imaging, and interpretation.
-
MK 0893: Discovery of a Glucagon Receptor Antagonist
2026-08-24
The reference study describes how lead optimization of a pyrazole-based scaffold produced MK 0893, a potent and selective competitive glucagon receptor antagonist with oral activity in diabetic animal models. Its combination of nanomolar receptor and cAMP potency, family B GPCR selectivity, and glucose-lowering efficacy established a useful foundation for type 2 diabetes research.
-
GSK J4 HCl: Practical Epigenetic Workflows
2026-08-23
GSK J4 HCl enables cell-based interrogation of JMJD3-linked H3K27 demethylation in inflammation, cancer, and chromatin-regulated transcription. This guide translates its prodrug behavior into practical dose selection, promoter-level assays, and troubleshooting strategies, while distinguishing direct evidence from exploratory applications.
-
Metabolomics Reveals Carbapenemase Resistance
2026-08-22
The reference study shows that LC-MS/MS profiling of intracellular and extracellular metabolites can distinguish carbapenemase-producing Enterobacterales from non-CPE isolates after short, antibiotic-free growth. Its combination of metabolite biomarkers, supervised machine learning, and pathway analysis offers a potential route to faster resistance detection while also highlighting metabolic features associated with the resistant phenotype.
-
Fangchinoline Restores Lysosomal Defense Against H1N1
2026-08-22
Cheng and colleagues identify fangchinoline as a lysosome-targeted antiviral that restores TFEB-dependent lysosomal gene expression and interferes with H1N1 entry. By combining Connectivity Map screening, transcriptomics, organelle assays, stage-resolved infection experiments, and in vivo validation, the study defines a host-directed strategy for countering influenza-associated lysosomal dysfunction.
-
GSK-923295 and the Mechanics of Mitotic Fidelity
2026-08-21
GSK-923295 is a CENP-E inhibitor for dissecting chromosome congression, mitotic arrest, and centromere-dependent fidelity. This article distinguishes motor inhibition from CTCF-linked centromere architecture defects to improve assay interpretation and cancer research design.